» Articles » PMID: 30190979

Hepatocellular Carcinoma Risk Scores: Ready to Use in 2015?

Overview
Journal Hepat Oncol
Date 2018 Sep 8
PMID 30190979
Citations 1
Authors
Affiliations
Soon will be listed here.
Citing Articles

Plasma DNA methylation marker and hepatocellular carcinoma risk prediction model for the general population.

Wu H, Yang H, Wang Q, Chen C, Santella R Carcinogenesis. 2017; 38(10):1021-1028.

PMID: 28981677 PMC: 5862336. DOI: 10.1093/carcin/bgx078.

References
1.
Fontana R, Dienstag J, Bonkovsky H, Sterling R, Naishadham D, Goodman Z . Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut. 2010; 59(10):1401-9. PMC: 3740000. DOI: 10.1136/gut.2010.207423. View

2.
Huang Y, Jen C, Yang H, Lee M, Su J, Lu S . Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol. 2011; 29(27):3643-50. PMC: 4874144. DOI: 10.1200/JCO.2011.36.2335. View

3.
Lee M, Yang H, Lu S, Jen C, You S, Wang L . Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma. Int J Cancer. 2014; 135(5):1119-26. DOI: 10.1002/ijc.28753. View

4.
Wong V, Chan S, Mo F, Chan T, Loong H, Wong G . Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010; 28(10):1660-5. DOI: 10.1200/JCO.2009.26.2675. View

5.
Yuen M, Tanaka Y, Fong D, Fung J, Wong D, Yuen J . Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2008; 50(1):80-8. DOI: 10.1016/j.jhep.2008.07.023. View